Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia

Mary Elizabeth Percival, Catherine Lai, Elihu Estey, Christopher Hourigan

Research output: Contribution to journalReview article

Abstract

The diagnosis of acute myeloid leukemia (AML) can be made based on peripheral blood or bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and peripheral blood monitoring in the diagnosis, management, and follow up of AML patients. For patients with circulating blasts, it is reasonable to perform the necessary studies needed for diagnosis and risk stratification, including multiparametric flow cytometry, cytogenetics, and molecular analysis, on a peripheral blood specimen. The day 14 marrow is used to document hypocellularity in response to induction chemotherapy, but it is unclear if that assessment is necessary as it often does not affect immediate management. Currently, response assessments performed at count recovery for evaluation of remission and measurable residual disease rely on bone marrow sampling. For monitoring of relapse, peripheral blood evaluation may be adequate, but the sensitivity of bone marrow testing is in some cases superior. While bone marrow evaluation can certainly be avoided in particular situations, this cumbersome and uncomfortable procedure currently remains the de facto standard for response assessment.

Original languageEnglish (US)
Pages (from-to)185-192
Number of pages8
JournalBlood Reviews
Volume31
Issue number4
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Bone Marrow
Induction Chemotherapy
Cytogenetic Analysis
Flow Cytometry
Recurrence

Keywords

  • Acute myeloid leukemia
  • Bone marrow evaluation
  • Flow cytometry
  • Measurable residual disease
  • Morphology

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. / Percival, Mary Elizabeth; Lai, Catherine; Estey, Elihu; Hourigan, Christopher.

In: Blood Reviews, Vol. 31, No. 4, 01.07.2017, p. 185-192.

Research output: Contribution to journalReview article

Percival, Mary Elizabeth ; Lai, Catherine ; Estey, Elihu ; Hourigan, Christopher. / Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. In: Blood Reviews. 2017 ; Vol. 31, No. 4. pp. 185-192.
@article{ef984883d4f3437d8c3f5e848d44c5d1,
title = "Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia",
abstract = "The diagnosis of acute myeloid leukemia (AML) can be made based on peripheral blood or bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and peripheral blood monitoring in the diagnosis, management, and follow up of AML patients. For patients with circulating blasts, it is reasonable to perform the necessary studies needed for diagnosis and risk stratification, including multiparametric flow cytometry, cytogenetics, and molecular analysis, on a peripheral blood specimen. The day 14 marrow is used to document hypocellularity in response to induction chemotherapy, but it is unclear if that assessment is necessary as it often does not affect immediate management. Currently, response assessments performed at count recovery for evaluation of remission and measurable residual disease rely on bone marrow sampling. For monitoring of relapse, peripheral blood evaluation may be adequate, but the sensitivity of bone marrow testing is in some cases superior. While bone marrow evaluation can certainly be avoided in particular situations, this cumbersome and uncomfortable procedure currently remains the de facto standard for response assessment.",
keywords = "Acute myeloid leukemia, Bone marrow evaluation, Flow cytometry, Measurable residual disease, Morphology",
author = "Percival, {Mary Elizabeth} and Catherine Lai and Elihu Estey and Christopher Hourigan",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.blre.2017.01.003",
language = "English (US)",
volume = "31",
pages = "185--192",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia

AU - Percival, Mary Elizabeth

AU - Lai, Catherine

AU - Estey, Elihu

AU - Hourigan, Christopher

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The diagnosis of acute myeloid leukemia (AML) can be made based on peripheral blood or bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and peripheral blood monitoring in the diagnosis, management, and follow up of AML patients. For patients with circulating blasts, it is reasonable to perform the necessary studies needed for diagnosis and risk stratification, including multiparametric flow cytometry, cytogenetics, and molecular analysis, on a peripheral blood specimen. The day 14 marrow is used to document hypocellularity in response to induction chemotherapy, but it is unclear if that assessment is necessary as it often does not affect immediate management. Currently, response assessments performed at count recovery for evaluation of remission and measurable residual disease rely on bone marrow sampling. For monitoring of relapse, peripheral blood evaluation may be adequate, but the sensitivity of bone marrow testing is in some cases superior. While bone marrow evaluation can certainly be avoided in particular situations, this cumbersome and uncomfortable procedure currently remains the de facto standard for response assessment.

AB - The diagnosis of acute myeloid leukemia (AML) can be made based on peripheral blood or bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and peripheral blood monitoring in the diagnosis, management, and follow up of AML patients. For patients with circulating blasts, it is reasonable to perform the necessary studies needed for diagnosis and risk stratification, including multiparametric flow cytometry, cytogenetics, and molecular analysis, on a peripheral blood specimen. The day 14 marrow is used to document hypocellularity in response to induction chemotherapy, but it is unclear if that assessment is necessary as it often does not affect immediate management. Currently, response assessments performed at count recovery for evaluation of remission and measurable residual disease rely on bone marrow sampling. For monitoring of relapse, peripheral blood evaluation may be adequate, but the sensitivity of bone marrow testing is in some cases superior. While bone marrow evaluation can certainly be avoided in particular situations, this cumbersome and uncomfortable procedure currently remains the de facto standard for response assessment.

KW - Acute myeloid leukemia

KW - Bone marrow evaluation

KW - Flow cytometry

KW - Measurable residual disease

KW - Morphology

UR - http://www.scopus.com/inward/record.url?scp=85011982199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011982199&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2017.01.003

DO - 10.1016/j.blre.2017.01.003

M3 - Review article

C2 - 28190619

AN - SCOPUS:85011982199

VL - 31

SP - 185

EP - 192

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 4

ER -